PAVmed
PAVM
73 hedge funds and large institutions have $11.5M invested in PAVmed in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 30 closing their positions.
71% more call options, than puts
Call options by funds: $154K | Put options by funds: $90K
9.44% less ownership
Funds ownership: 23.21% → 13.77% (-9.4%)
22% less funds holding
Funds holding: 94 → 73 (-21)
57% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 30
64% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 28
79% less capital inflows, than outflows
Capital inflows: $2.59M | Capital outflows: $12.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.7M |
| 2 |
E
Ergoteles
New York
|
+$384K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$68.6K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$41.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$37.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.52M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.26M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$874K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$808K |
| 5 |
Two Sigma Advisers
New York
|
-$792K |
PAVM Hedge Fund Activity: Q2 2022 in Review
73 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q2 2022, worth a combined $11.5M — down 58% from $27M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PAVM and 13 opened new positions — a net loss of 17 holders — while 28 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.7M. The largest seller was BlackRock, cutting an estimated $3.52M.
- 73 institutional investors held PAVmed (PAVM) as of Q2 2022, down from 94 in Q1 2022.
- Funds reported $11.5M of PAVmed stock for Q2 2022, down 58% quarter-over-quarter.
- 13 funds opened new PAVmed positions in Q2 2022 and 30 closed out, a net change of -17 holders.
- The largest PAVmed buyer in Q2 2022 was Millennium Management, an estimated $1.7M added.
- The largest PAVmed seller in Q2 2022 was BlackRock, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2022.